Status:
COMPLETED
Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients
Lead Sponsor:
Zealand University Hospital
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Personalized therapy as prophylaxis in ischemic stroke patients is not yet an option. From patients with ischemic heart disease, we know that patients with in vitro high on treatment platelet reactivi...
Detailed Description
Background: Clopidogrel (CLO) is a pro-drug metabolized in the liver by the Cytochrom-P450 system to its active component. Studies in acute ischemic stroke (IS) patients have proven that genetic diffe...
Eligibility Criteria
Inclusion
- Ischemic stroke diagnosis
- treatment with clopidogrel 75 mg/day
Exclusion
- increased risk of bleeding
- treatment with NOAC, vitamin K antagonist or other antiplatelet drug than clopidogrel
- unable to give informed consent
Key Trial Info
Start Date :
November 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2017
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT03385538
Start Date
November 1 2015
End Date
July 30 2017
Last Update
December 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zealand University Hospital, dept of neurology
Roskilde, Denmark, 4000